{"commentary":{"count":20,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":9,"x_thread":6,"podcast":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04564703\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04564703","nct_id":"NCT04564703","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04564703. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Iberdomide will be given orally at 1.3 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.","label":"cohort 1","type":"EXPERIMENTAL"},{"description":"Iberdomide will be given orally at 1.0 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.","label":"cohort 2","type":"EXPERIMENTAL"},{"description":"Iberdomide will be given orally at 0.75 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.","label":"cohort 3","type":"EXPERIMENTAL"}],"collaborators":["Healt Data Specialists - HeaDS (CRO)","EMN Research Italy Impresa Sociale Srl"],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":160,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Iberdomide","type":"DRUG"}],"last_update":"2026-07-16","lead_sponsor":"Stichting European Myeloma Network","official_title":"Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2023-07-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Efficacy: rate of improvement in response with iberdomide maintenance after autologous stem cell transplantation (ASCT)","timeFrame":"6 months of treatment"},{"measure":"Rate of dose reductions/discontinuations with iberdomide maintenance after ASCT","timeFrame":"6 months of treatment"}],"references":[],"start_date":{"date":"2021-02-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients","url":"https://clinicaltrials.gov/study/NCT04564703"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04564703"}